Digital Health Tool for Improving Medication Adherence in Diabetes

JS
Overseen ByJacqueline Seiglie
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Massachusetts General Hospital
Must be taking: Diabetes medications
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to test a new text message tool designed to help Latino adults with type 2 diabetes adhere to their medication regimen. The tool sends daily messages about diet, exercise, and medication reminders, along with weekly feedback on medication-taking habits. Participants may be a good fit if they have type 2 diabetes, have struggled with regular medication adherence, and prefer receiving messages in Spanish. This tool could simplify diabetes management and reduce complications for Latino adults in the U.S. As an unphased trial, the study offers a unique opportunity to contribute to innovative solutions for diabetes management.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, since the study focuses on improving adherence to diabetes medications, it seems likely that you will continue taking them.

What prior data suggests that this digital health tool is safe for improving medication adherence in diabetes?

Research shows that the REACH-Es digital health tool, which uses text messages to assist people in taking their diabetes medication, has been well-received by adults with type 2 diabetes from various backgrounds. Studies indicate that participants responded positively to the text messages, which helped them manage their diabetes better without any major side effects. This suggests the tool is safe for people with diabetes.

The Enhanced Treatment as Usual (ETAU) approach includes standard medical care, which remains safe as it follows established medical guidelines. Adding occasional informative text messages is unlikely to cause any safety issues.

Overall, both REACH-Es and ETAU aim to help manage diabetes without introducing significant risks.12345

Why are researchers excited about this trial?

Researchers are excited about these treatments because they aim to enhance medication adherence in diabetes, a critical aspect of effective disease management. Unlike traditional diabetes treatments that focus solely on medication and physician monitoring, the REACH-Es tool uniquely integrates technology by using daily SMS messages to provide personalized information and feedback on diet, exercise, and medication adherence. This includes interactive two-way messaging to engage participants actively in their care. The Enhanced Treatment as Usual (ETAU) also introduces digital elements by providing patients with updates and educational content via SMS, promoting better self-care. These innovations have the potential to improve how patients stick to their treatment plans, potentially leading to better health outcomes.

What evidence suggests that this digital health tool is effective for improving medication adherence in diabetes?

Research shows that the REACH-Es tool, which participants in this trial may receive, uses text messages to help people with diabetes take their medicines more regularly. Studies on similar text messaging tools have found that they can help people remember to take their medication more often. This is especially important for Latino individuals who face more challenges in managing diabetes. The REACH-Es system sends daily messages about diet, exercise, and medicine, along with regular updates on blood sugar levels. This approach aims to make it easier for people to manage their diabetes and reduce complications. Participants in the Enhanced Treatment As Usual (ETAU) arm will continue their usual care with additional educational messages and updates.23678

Who Is on the Research Team?

JS

Jacqueline Seiglie

Principal Investigator

Massachusetts General Hospital

Are You a Good Fit for This Trial?

This trial is for Latino adults with type 2 diabetes who prefer to speak and read Spanish, have had suboptimal medication adherence, and an HbA1c level of ≥8.0% since 2018. Participants must be over 18, use a mobile phone with texting, and receive care at MGH-affiliated practices. Those with hearing issues or unable to handle text messages are excluded.

Inclusion Criteria

Your average blood sugar level, measured over the past few months, is 8.0% or higher.
Willing and able to provide informed consent
Receive care at MGH-affiliated primary care practices (≥2 visits in the past 3 years)
See 6 more

Exclusion Criteria

I have hearing difficulties or cannot speak.
Inability to receive, read, or send a text message (assessed by a trained research assistant)

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the REACH-Es intervention, including daily and weekly SMS related to diabetes management and adherence

6 months
Daily SMS interactions, weekly feedback SMS

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • ETAU
  • REACH-Es
Trial Overview The study tests REACH-Es, a digital health tool delivering tailored interactive text messages designed to help Latino adults overcome barriers to taking their diabetes medications consistently.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: REACH-EsExperimental Treatment1 Intervention
Group II: Enhanced treatment as usual (ETAU)Active Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials
3,066
Recruited
13,430,000+

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Trials
2,513
Recruited
4,366,000+

Published Research Related to This Trial

A Spanish-language text messaging program significantly improved diabetes management in Latinos, resulting in a median HbA1c reduction of 1.4 percentage points after 3 months among 38 participants.
Participants with higher initial HbA1c levels (over 10.0%) experienced even greater reductions (3.8 percentage points), indicating that this intervention may be particularly beneficial for those with more severe diabetes.
Evaluating the Impact of Mobile Phone Technology on Health Outcomes for Latinos with Type 2 Diabetes.Jackson, LV., Carpenter, DM., Postlethwaite, DA., et al.[2021]
A cloud-based multimedia application was tested on 297 patients and showed a 43.4% relative improvement in adherence to endoscopy preparation procedures, indicating its potential effectiveness.
Involving healthcare providers in the design and evaluation of patient education applications may enhance their effectiveness and encourage wider adoption among patients.
Cloud-based multi-media systems for patient education and adherence: a pilot study to explore patient compliance with colonoscopy procedure preparation.Schooley, B., San Nicolas-Rocca, T., Burkhard, R.[2021]
In a study involving 310 adults with type 2 diabetes, those who received Conversation Maps™ (CM) education showed significantly higher diabetes knowledge scores compared to those receiving regular care (RC) at both 2 and 6 months after the intervention (p<0.001).
While there were no significant differences in clinical outcomes between the two groups, the CM group reported higher satisfaction with care and a better perception of goal attainment, indicating that CM may enhance the educational experience for patients with diabetes.
Impact of the «Conversation Map™» tools on understanding of diabetes by Spanish patients with type 2 diabetes mellitus: a randomized, comparative study.Penalba, M., Moreno, L., Cobo, A., et al.[2016]

Citations

Adapting a Text Messaging Intervention to Improve Diabetes ...This study aimed to report the multiphase, stakeholder-driven adaptation of the REACH barriers to diabetes medication adherence content to a Latino population.
Rapid Education/Encouragement And Communications for ...Conclusions This review highlights critical factors influencing the design of SMS text messaging interventions for medication adherence in the management of ...
Mass General - Division of Clinical ResearchThe goal of REACH-Español is to improve diabetes medication adherence ... One such mHealth platform is REACH (Rapid Encouragement/Education And Communications for ...
Digital Health Tool for Improving Medication Adherence in ...ETAU, REACH-Es is unique because it integrates digital health tools to provide tailored education and reminders, which can help improve medication adherence in ...
5.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/40311126/
Adapting a Text Messaging Intervention to Improve Diabetes ...This study aimed to report the multiphase, stakeholder-driven adaptation of the REACH barriers to diabetes medication adherence content to a Latino population.
The REACH ProgramThe REACH Study had excellent long-term retention and intervention engagement among diverse adults with type 2 diabetes. • REACH improved clinical and ...
Adapting a text messaging intervention to improve diabetes ...Objective This study aimed to report the multiphase, stakeholder-driven adaptation of the REACH barriers to diabetes medication adherence ...
8.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/33154039/
Effects of a Tailored Text Messaging Intervention Among ...REACH engaged at-risk patients in diabetes self-management and improved short-term HbA 1c . More than texts alone may be needed to sustain the effects.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security